文献速递肾移植

自体耐受性树突状细胞免疫治疗在肾移植受者中的I/IIa期研究

A Phase I/IIa study of autologous tolerogenic dendritic cells immunotherapy in kidney transplant recipients.
PubMed 文献 · Kidney Int · 2022-10-26

该I/IIa期临床试验在8例肾移植受者中于移植前一天输注自体耐受性树突状细胞(ATDC),联合标准免疫抑制并可选减撤吗替麦考酚酯,对照组9例接受巴利昔单抗诱导且不允许减撤吗替麦考酚酯。随访三年无死亡、移植物存活率100%,ATDC输注未显著增加不良事件,排斥反应在ATDC组2例、对照组1例且均经糖皮质激素成功治疗,ATDC组5例成功减量或停用吗替麦考酚酯,其中2例实现他克莫司单药治疗。

要点

  • 8例肾移植受者移植前一天输注ATDC,联合标准免疫抑制并可选减撤吗替麦考酚酯。
  • 随访三年无死亡、移植物存活率100%,ATDC输注未显著增加不良事件。
  • 排斥反应ATDC组2例、对照组1例,均经糖皮质激素成功治疗。

核心结论

  • 结果表明ATDC在肾移植受者中给药是安全的。

研究设计与样本

  • I/IIa期临床试验,8例肾移植受者接受ATDC(移植前一天输注)联合标准免疫抑制,对照组9例接受相同标准免疫抑制但以巴利昔单抗诱导替代ATDC且不允许减撤吗替麦考酚酯。
  • ATDC制剂在符合药品生产质量管理规范(GMP)的设施中制备,并满足细胞计数、活力、纯度和鉴别标准方可放行。

主要发现

  • 随访三年期间无死亡,移植物存活率100%。
  • ATDC输注未显著增加不良事件。
  • 排斥反应见于ATDC组2例和对照组1例,所有排斥反应均经糖皮质激素成功治疗。
  • ATDC组5例成功减量或停用吗替麦考酚酯,其中2例实现他克莫司单药治疗。
  • 免疫监测显示ATDC组CD8 T细胞活化标志物降低、Foxp3表达增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kidney transplant survival is shortened by chronic rejection and side effects of standard immunosuppressive drugs. Cell-based immunotherapy with tolerogenic dendritic cells has long been recognized as a promising approach to reduce general immunosuppression. Published trials report the safety and the absence of therapy-related adverse reactions in patients treated with tolerogenic dendritic cells suffering from several inflammatory diseases. Here, we present the first phase I clinical trial results using human autologous tolerogenic dendritic cells (ATDC) in kidney transplantation. Eight patients received ATDC the day before transplantation in conjunction with standard steroids, mycophenolate mofetil and tacrolimus immunosuppression with an option to taper mycophenolate mofetil. ATDC preparations were manufactured in a Good Manufacturing Practice-compliant facility and fulfilled cell count, viability, purity and identity criteria for release. A control group of nine patients received the same standard immunosuppression, except basiliximab induction replaced ATDC therapy and mycophenolate tapering was not allowed. During the three-year follow-up, no deaths occurred and there was 100% graft survival. No significant increase of adverse events was associated with ATDC infusion. Episodes of rejection were observed in two patients from the ATDC group and one patient from the control group. However, all rejections were successfully treated by glucocorticoids. Mycophenolate was successfully reduced/stopped in five patients from the ATDC group, allowing tacrolimus monotherapy for two of them. Regarding immune monitoring, reduced CD8 T cell activation markers and increased Foxp3 expression were observed in the ATDC group. Thus, our results demonstrate ATDC administration safety in kidney-transplant recipients.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Moreau A, Kervella D, Bouchet-Delbos L, et al. A Phase I/IIa study of autologous tolerogenic dendritic cells immunotherapy in kidney transplant recipients. Kidney Int. 2022. PMID: 36306921. doi:10.1016/j.kint.2022.08.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。